Other Services

This Service

A database built with INDRA combining content from numerous readers and databases. This page allows you to curate the loaded statements. For more information please see the manual.

This Project

INDRA is developed by indralabs, a part of the Harvard Medical School Laboratory of Systems Pharmacology.

This project, indra_db, is also developed by the indralab team. For more information on how we procure our sources, you can go here. This work was funded by ARO grant W911NF‐15‐1‐0544 under the DARPA Communicating with Computers program.

IndraLab

Statements

EIF3H binds MYC. 1 / 1

| 1

➶

sparser

"Among patients with amplification of both HER2 and MYC , the addition of trastuzumab to chemotherapy reduced the risk of cancer recurrence by 76% and reduced the risk of death by 64%, while in individuals with HER2 amplification alone the addition of trastuzumab to chemotherapy did not reduce the risk of death. xref In our study, we observed that both MYC and EIF3H were associated with a better outcome after gefitinib therapy, and among EGFR+ patients (FISH+ and/or mutated), only individuals with increased MYC/EIF3H gene copy number had a significant tumor shrinkage."

19204574

Our Sources:

INDRA allows us to combine the results from a multitude of sources. In particular, the INDRA Database draws on the following...